About us
Aerska focuses on creating RNA interference (RNAi) medicines designed to treat, delay, and prevent neurological diseases by silencing genes that cause harm. Their mission is to preserve cognitive functions and enhance the quality of life for individuals affected by these conditions. The company's approach is built on three key pillars: developing next-generation RNA medicines, utilizing systemic administration with targeted delivery to the brain, and implementing precision medicine strategies to transform central nervous system (CNS) treatments. By leveraging advancements in brain delivery technologies, Aerska aims to transport RNA therapeutics across the blood-brain barrier, offering less invasive and more effective treatments for CNS diseases. Their work is grounded in the belief that precision medicine, which has transformed cancer care, can similarly revolutionize the treatment of neurological disorders. By combining target biology, data-driven patient stratification, and biomarker-guided development, they strive to bring personalized medicine to CNS diseases, potentially transforming how brain disorders are treated—one patient, one gene, one memory at a time.
Open positions